Atara Biotherapeutics Inc (NASDAQ:ATRA) Insider Sells $58,502.57 in Stock

Atara Biotherapeutics Inc (NASDAQ:ATRA) insider Joe Newell sold 4,117 shares of the business’s stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $14.21, for a total transaction of $58,502.57. Following the completion of the sale, the insider now owns 53,881 shares of the company’s stock, valued at approximately $765,649.01. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

NASDAQ:ATRA opened at $14.24 on Thursday. The company has a market cap of $778.14 million, a PE ratio of -2.33 and a beta of 2.08. Atara Biotherapeutics Inc has a twelve month low of $10.38 and a twelve month high of $41.97. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.05. The company’s 50 day moving average is $15.17 and its two-hundred day moving average is $14.13.

ATRA has been the topic of a number of analyst reports. BidaskClub downgraded shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, January 25th. JPMorgan Chase & Co. downgraded shares of Atara Biotherapeutics from an “overweight” rating to a “neutral” rating and cut their price objective for the stock from $43.00 to $22.00 in a research report on Friday, November 8th. Cowen reaffirmed a “buy” rating on shares of Atara Biotherapeutics in a research report on Tuesday, December 10th. Zacks Investment Research downgraded shares of Atara Biotherapeutics from a “buy” rating to a “sell” rating in a research report on Friday, January 10th. Finally, Stifel Nicolaus reaffirmed a “buy” rating on shares of Atara Biotherapeutics in a research report on Friday, October 25th. Three research analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have issued a buy rating to the company. Atara Biotherapeutics presently has a consensus rating of “Hold” and an average price target of $28.22.

Large investors have recently added to or reduced their stakes in the business. Credit Suisse AG raised its position in shares of Atara Biotherapeutics by 78.9% in the fourth quarter. Credit Suisse AG now owns 58,559 shares of the biotechnology company’s stock valued at $964,000 after buying an additional 25,818 shares during the last quarter. Raymond James & Associates raised its position in shares of Atara Biotherapeutics by 4.6% in the fourth quarter. Raymond James & Associates now owns 21,166 shares of the biotechnology company’s stock valued at $349,000 after buying an additional 932 shares during the last quarter. Citigroup Inc. raised its position in shares of Atara Biotherapeutics by 20.2% in the fourth quarter. Citigroup Inc. now owns 182,024 shares of the biotechnology company’s stock valued at $2,998,000 after buying an additional 30,609 shares during the last quarter. Great West Life Assurance Co. Can acquired a new stake in shares of Atara Biotherapeutics in the fourth quarter valued at about $88,000. Finally, Vident Investment Advisory LLC raised its position in shares of Atara Biotherapeutics by 51.8% in the fourth quarter. Vident Investment Advisory LLC now owns 97,273 shares of the biotechnology company’s stock valued at $1,602,000 after buying an additional 33,210 shares during the last quarter.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Featured Article: Beige Book

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.